Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.40 |
| ▸ | TET3 | O43151 | 7/20 | 0.40 |
| ▸ | FBXL19 | Q6PCT2 | 7/20 | 0.40 |
| ▸ | CXXC5 | Q7LFL8 | 7/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 7/20 | 0.40 |
| ▸ | CXXC4 | Q9H2H0 | 7/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 7/20 | 0.40 |
| ▸ | TET1 | Q8NFU7 | 5/20 | 0.40 |
| ▸ | BTK | Q06187 | 5/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21303477 | 0.92 | BTK (0.39) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL16074977 | 0.92 | BTK (0.39) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL15474352 | 0.83 | BTK (0.41) | BTKTEAD1JAK3 | |
| SCHEMBL16375281 | 0.83 | CYP2D6 (0.41) | BTKHRH3CYP1A2CYP2C9JAK3 | |
| SCHEMBL16380338 | 0.81 | KMT2A (0.43) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL14670982 | 0.80 | CYP3A4 (0.45) | KMT2ACYP1A2CYP2C9 | |
| SCHEMBL26294933 | 0.78 | BTK (0.36) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL17150549 | 0.78 | TET3 (0.43) | KMT2ATET3FBXL19CXXC5KDM2B | |
| SCHEMBL26501046 | 0.78 | CHRNB2 (0.38) | KMT2AHRH3CYP1A2CYP2C9 | |
| SCHEMBL409261 | 0.78 | TEAD1 (0.45) | KMT2ATET3FBXL19CXXC5KDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426637-B1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ANGEL PHARMACEUTICAL CO LTD (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-29 | — | — | US | disclosed |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-04-18 | — | — | US | disclosed |
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS BIOPHARMACEUTICALS, LTD. (KY) | 2019-04-11 | — | — | US | disclosed |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-9458162-B2 | Cyclic molecules as bruton's tyrosine kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | KMT2A 1371/4885TET3 1686/4885FBXL19 1921/4885 |
| US-20180086748-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | KMT2A 1186/4885TET3 2626/4885FBXL19 1251/4885 |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, PRKACA | KMT2A 1446/4885TET3 4166/4885FBXL19 1726/4885 |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | ABL1, BTK, LYN | KMT2A 1371/4885TET3 1686/4885FBXL19 1921/4885 |
| US-10875852-B2 | Heteroaromatic compounds as BTK inhibitors | BTK, SYK, LCK | KMT2A 1186/4885TET3 2626/4885FBXL19 1251/4885 |
| US-20190112302-A1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LCK | KMT2A 1186/4885TET3 2626/4885FBXL19 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.